BioCritica

Lilly and investor group form new critical-care company BioCritica

Monday, May 23, 2011

Eli Lilly has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica, a newly-formed and privately held biotechnology company. BioCritica, based in Central Indiana, will initially focus on the continued U.S. development and commercialization of Xigris (drotrecogin alfa (activated)), Lilly’s medicine for severe sepsis. BioCritica intends to ultimately build a broad portfolio of innovative, hospital-based critical care medicines.

[Read More]